Engineers Gate Manager’s BioCryst Pharmaceuticals BCRX Stock Holding History

Engineers Gate Manager’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.75M	Sell	175,002 -19,473	-10%	-$176K	0.02%	765
2026 Q1	$1.85M	Sell	194,475 -30,068	-13%	-$234K	0.02%	744
2025 Q4	$1.75M	Sell	224,543 -218,304	-49%	-$1.58M	0.02%	757
2025 Q3	$3.36M	Buy	442,847 +301,341	+213%	+$2.51M	0.04%	529
2025 Q2	$1.27M	Buy	141,506 +28,452	+25%	+$265K	0.02%	989
2025 Q1	$848K	Buy	113,054 +89,804	+386%	+$724K	0.01%	1158
2024 Q4	$175K	Sell	23,250 -39,060	-63%	-$297K	﹤0.01%	1909
2024 Q3	$474K	Buy	62,310 +33,330	+115%	+$253K	0.01%	1401
2024 Q2	$179K	Sell	28,980 -12,300	-30%	-$67.9K	﹤0.01%	1662
2024 Q1	$210K	Sell	41,280 -13,740	-25%	-$77.3K	0.01%	1633
2023 Q4	$330K	Sell	55,020 -11,880	-18%	-$68.8K	0.01%	1403
2023 Q3	$474K	Buy	66,900 +33,000	+97%	+$237K	0.02%	1085
2023 Q2	$239K	Sell	33,900 -33,692	-50%	-$270K	0.01%	1403
2023 Q1	$564K	Buy	+67,592	New	+$651K	0.02%	917
2022 Q4	–	Sell	-54,467	Closed	-$686K	–	1679
2022 Q3	$686K	Buy	+54,467	New	+$701K	0.04%	614
2021 Q3	–	Sell	-34,820	Closed	-$551K	–	1644
2021 Q2	$551K	Buy	+34,820	New	+$473K	0.04%	777
2020 Q2	–	Sell	-10,000	Closed	-$20K	–	1690
2020 Q1	$20K	Buy	+10,000	New	+$27.5K	﹤0.01%	1516

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Engineers Gate Manager's BCRX Position: Q2 2026 in Review

Engineers Gate Manager reduced its BioCryst Pharmaceuticals (BCRX) stake by 10% in Q2 2026, selling an estimated $176K and leaving 175,002 shares worth $1.75M. The position accounts for 0.02% of the portfolio, ranked #765.

Engineers Gate Manager first reported a position in BCRX in Q1 2020 and has held it in 17 quarters since. The position peaked at $3.36M in Q3 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Engineers Gate Manager held 175,002 shares of BioCryst Pharmaceuticals worth $1.75M as of Q2 2026.
Engineers Gate Manager sold 19,473 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $176K.
BioCryst Pharmaceuticals made up 0.02% of Engineers Gate Manager's portfolio in Q2 2026, its #765 holding.
Engineers Gate Manager first reported a position in BioCryst Pharmaceuticals in Q1 2020 and has held it in 17 quarters since.
Engineers Gate Manager's BioCryst Pharmaceuticals position peaked at $3.36M in Q3 2025.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.